Zhejiang Sunflower Great Health Co Ltd
Zhejiang Sunflower Great Health Co Ltd is a Chinese pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily in the domestic market.
Business. Zhejiang Sunflower Great Health Co Ltd (300111.SZ) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in China and primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data. Consequently, the company is described at the industry level within the broader pharmaceuticals sector.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Zhejiang Sunflower Great Health Co Ltd (300111.SZ) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in China and primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data. Consequently, the company is described at the industry level within the broader pharmaceuticals sector.
Zhejiang Sunflower Great Health Co Ltd has a market price of 3.48 CNY per share, with a market capitalization of 4,479,493,284.72 CNY. The company's price-to-book ratio is 6.57, and its price-to-tangible-book ratio is also 6.57, indicating a premium valuation relative to its book value. The enterprise value to revenue ratio is 16.49, and the enterprise value to EBITDA ratio is -832.79, which is not meaningful due to the company's negative EBITDA.
The company's profitability metrics are weak, with a return on equity of -0.64% and a return on assets of -0.45%, both significantly below the industry median for pharmaceutical companies. The company reported a net loss of 4,384,750 CNY and an operating loss of 5,375,310 CNY in the latest period. Despite these losses, the company maintains a strong liquidity position, with a current ratio of 6.23 and a debt-to-equity ratio of 0.0, indicating no long-term debt.
The company's revenue is concentrated in a single geographic market, with no disclosed segment breakdown, suggesting a high degree of geographic concentration risk. The company's operating cash flow is positive at 4,197,350 CNY, and its free cash flow is 1,610,150 CNY, indicating that it is generating cash despite its net loss.
The company's growth trajectory is uncertain, with no disclosed revenue growth or decline in the latest period. The company's capital expenditures were -9,756,520 CNY, indicating a reduction in capital spending. The company's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected.
Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's financial snapshot does not include any recent events or transcripts that would suggest a material change in its business outlook.
- The company is trading at a premium to book value, with a price-to-book ratio of 6.57.
- The company is unprofitable, with a return on equity of -0.64% and a return on assets of -0.45%.
- The company has no long-term debt and a strong liquidity position, with a current ratio of 6.23.
- The company's revenue is concentrated in a single geographic market, indicating a high degree of geographic concentration risk.
- The company is generating positive operating and free cash flow despite its net loss.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Zhejiang Sunflower Great Health Co Ltd Market data — financials · 2026-05-26